Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials01:16

Clinical Trials

8.5K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
8.5K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.7K
Preclinical Development: Overview01:28

Preclinical Development: Overview

4.8K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Health Equity Barriers to Accessing Vaccination and Screening Services in Low- and Middle-Income Countries: A Narrative Review.

Risk management and healthcare policy·2026
Same author

Safety and Immunogenicity of a Locally Produced Inactivated NDV-HXP-S COVID-19 Vaccine (HXP-GPOVac) Compared with BNT162b2: A Phase II Randomized, Controlled, Double-Blind Noninferiority Trial in Thai Adults.

Vaccines·2026
Same author

Vaginal Microbiota and Cytokines Among Pregnant and Breastfeeding Women in Clinical Trials of the Dapivirine Vaginal Ring and Oral Tenofovir Disoproxil Fumarate/Emtricitabine.

Open forum infectious diseases·2026
Same author

Comparative Genomics of <i>Escherichia coli</i> Serogroups 64474, O179, O188 and <i>Shigella boydii</i> O16.

Pathogens (Basel, Switzerland)·2026
Same author

Efficacy of repair techniques for meniscal root tears: a systematic review and meta-analysis.

BMC musculoskeletal disorders·2026
Same author

Advancing national preparedness for the introduction of novel tuberculosis vaccines in South Africa: policy, evidence, and system readiness insights from a national workshop.

Vaccine·2026

Related Experiment Video

Updated: May 5, 2026

Zika Virus Specific Diagnostic Epitope Discovery
11:37

Zika Virus Specific Diagnostic Epitope Discovery

Published on: December 12, 2017

7.7K

Measles-Rubella Microarray Patches Phase III Clinical Trial Framework: Proposal and Considerations.

Darin Zehrung1, Bruce L Innis2, Auliya A Suwantika3

  • 1World Health Organization, 1211 Geneva, Switzerland.

Vaccines
|November 26, 2024
PubMed
Summary
This summary is machine-generated.

The Measles-Rubella Microarray Patch (MR-MAP) shows promise for improving vaccine coverage. A Phase III trial framework is proposed to assess its safety and immunogenicity compared to traditional injections in infants.

Keywords:
clinical trialmeaslesmicropatchrubellavaccines

More Related Videos

Multiplexed Isothermal Amplification Based Diagnostic Platform to Detect Zika, Chikungunya, and Dengue 1
06:18

Multiplexed Isothermal Amplification Based Diagnostic Platform to Detect Zika, Chikungunya, and Dengue 1

Published on: March 13, 2018

14.2K
Use of an Influenza Antigen Microarray to Measure the Breadth of Serum Antibodies Across Virus Subtypes
08:52

Use of an Influenza Antigen Microarray to Measure the Breadth of Serum Antibodies Across Virus Subtypes

Published on: July 26, 2019

8.1K

Related Experiment Videos

Last Updated: May 5, 2026

Zika Virus Specific Diagnostic Epitope Discovery
11:37

Zika Virus Specific Diagnostic Epitope Discovery

Published on: December 12, 2017

7.7K
Multiplexed Isothermal Amplification Based Diagnostic Platform to Detect Zika, Chikungunya, and Dengue 1
06:18

Multiplexed Isothermal Amplification Based Diagnostic Platform to Detect Zika, Chikungunya, and Dengue 1

Published on: March 13, 2018

14.2K
Use of an Influenza Antigen Microarray to Measure the Breadth of Serum Antibodies Across Virus Subtypes
08:52

Use of an Influenza Antigen Microarray to Measure the Breadth of Serum Antibodies Across Virus Subtypes

Published on: July 26, 2019

8.1K

Area of Science:

  • Vaccinology
  • Clinical Trial Design
  • Public Health Interventions

Background:

  • The Measles-Rubella Microarray Patch (MR-MAP) technology aims to address coverage and equity gaps in measles-containing vaccines (MCVs).
  • MR-MAPs are designed for easier programmatic deployment and administration by less-trained health workers, potentially increasing immunization coverage.
  • A Phase I/II trial has established the clinical proof-of-concept for MR-MAPs in infants and young children.

Purpose of the Study:

  • To present a framework for the pivotal Phase III clinical trial of MR-MAPs.
  • To outline considerations for trial design, regulatory approval, and World Health Organization (WHO) prequalification.
  • To inform policy decisions regarding the implementation of MR-MAP technology.

Main Methods:

  • A proposed Phase III trial will compare the immunogenicity and safety of MR-MAP against subcutaneous MR vaccine in 9- to 10-month-old infants.
  • Non-inferiority of immunogenicity will be assessed six weeks post-first dose.
  • A potential second dose and subsequent follow-ups are included for further safety and immunogenicity evaluation, if required by regulatory bodies.

Main Results:

  • The proposed trial framework is anticipated to generate essential clinical data for MR-MAP regulatory licensure and WHO prequalification.
  • The trial design requires confirmation by national regulatory authorities and the WHO prequalification team.
  • Further studies may be needed for concomitant vaccine delivery, broader age groups, and impact on coverage/equity.

Conclusions:

  • The developed Phase III trial framework provides a pathway for evaluating the MR-MAP.
  • Successful completion of the trial is expected to support regulatory approval and WHO prequalification.
  • Additional research is necessary to fully understand the potential of MR-MAPs in diverse settings and populations.